ATHE
- Alterity Therapeutics Limited
()
Overview
Company Summary
Alterity Therapeutics Limited (ATHE) is a pharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company is particularly dedicated to addressing Parkinson's disease and other related disorders, including Multiple System Atrophy (MSA) and Alzheimer's disease.
Alterity Therapeutics aims to provide novel therapies that can effectively prevent or halt the progression of these debilitating conditions, ultimately improving patients' quality of life. The company's primary focus is on Iron-Regulatory Protein (IRP) inhibitors, which hold significant potential in the treatment of neurodegenerative diseases.
ATHE's IRP inhibitors target a specific protein known as IRP2, which plays a crucial role in regulating iron metabolism in the brain. By inhibiting IRP2, Alterity Therapeutics seeks to restore iron homeostasis and prevent the associated toxic accumulation of iron in affected brain regions. This approach has shown promising preclinical results, suggesting that it could provide a much-needed therapeutic avenue for neurodegenerative diseases.
Alterity Therapeutics is actively involved in conducting clinical trials to evaluate the safety and efficacy of their IRP inhibitors. These trials involve rigorous testing of the compounds in human subjects to assess their potential benefits and any potential side effects. The company's ultimate goal is to secure regulatory approval for their treatments and make them available to patients worldwide.
In addition to its drug development activities, ATHE also engages in collaborative partnerships with academic institutions and other pharmaceutical companies to leverage their resources and expertise in advancing their research and development efforts. This approach enables Alterity Therapeutics to tap into a broader network of knowledge and accelerate the discovery and development of innovative therapies.
Overall, Alterity Therapeutics is committed to delivering disease-modifying treatments for neurodegenerative diseases, offering hope to patients, healthcare providers, and the wider medical community in combating these challenging conditions.